We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Lantheus Holdings Inc (LNTH) USD0.01

Sell:$84.66 Buy:$93.25 Change: $0.29 (0.32%)
NASDAQ:1.35%
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$84.66
Buy:$93.25
Change: $0.29 (0.32%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$84.66
Buy:$93.25
Change: $0.29 (0.32%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.

Contact details

Address:
331 Treble Cove Rd
NORTH BILLERICA
01862
United States
Telephone:
+1 (978) 6718001
Website:
https://www.lantheus.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LNTH
ISIN:
US5165441032
Market cap:
$6.33 billion
Shares in issue:
69.53 million
Sector:
Health Care Supplies
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Mary Heino
    Chairman of the Board
  • Paul Blanchfield
    President
  • Brian Markison
    Chief Executive Officer, Director
  • Robert Marshall
    Chief Financial Officer, Treasurer
  • Jamie Spaeth
    Chief People Officer
  • Daniel Niedzwiecki
    Chief Administrative Officer, General Counsel, Corporate Secretary
  • Jean-Claude Provost
    Chief Scientific Officer
  • Jeffrey Humphrey
    Chief Medical Officer
  • Etienne Montagut
    Chief Business Officer
  • Amanda Morgan
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.